AST-120 (KREMEZIN®), an alternative CKD treatment, is an oral spherical carbon adsorbent consisting of porous carbon particles that are 0.2–0.4 mm in diameter and insoluble in water. AST-120 treats uremic symptoms and prolongs the time to initiation of dialysis in patients with progressive CKD.

AST-120 (KREMEZIN®) consists of oral, spherical carbon particles that adsorb uremic toxins and their precursors within the gastrointestinal tract, allowing them to be excreted in the feces.

Background: AST-120 (Kremezin), which is an oral spherical carbon adsorbent, has been reported to have the potential for retarding disease progression in patients with chronic kidney disease. We aimed to evaluate its efficacy and safety in this study.

Kremezin drug information: uses, indications, side effects, dosage. Compare prices for generic kremezin substitutes: AST-120, Spherical carbon adsorbent

2005年8月3日 · Background: AST-120 (Kremezin; Kureha Chemical Industry Co Ltd, Tokyo, Japan) is an orally administered adsorbent showing adsorption ability superior to activated charcoal for certain organic compounds known to be precursors of substances that accumulate in patients with chronic kidney disease (CKD) and that are believed to accelerate the ...

This is the first network meta-analysis on AST-120 (Kremezin) in patients with CKD. AST-120, particularly tailored treatment or middle-dose therapy (approximately 6 g per day), appears to reduce composite renal outcomes and progression to end-stage renal disease.

KREMEZIN® is the world's first drug for chronic renal failure absorbing uremic toxins in the gastrointestinal tract of chronic renal failure by excreting the toxins with the feces, without being absorbed into the body.

For improvement in uremic symptoms and for prolonging the time to initiation of dialysis in chronic renal failure (progressive). For oral use, the usual adult dosage is 6 g of SPHERICAL CARBON ADSORBENT (Kremezin) divided 3 times daily.

When this product is administered orally to patients with chronic renal failure in the conservative therapy, it inhibits the increase of serum creatinine, improves uremic symptoms and prolongs the time to the initiation of dialysis.

2007年11月29日 · Kremezin is made by the Japanese Kureha Corporation and is currently available for therapeutic use in Japan and Korea for chronic renal failure. It is also available for the same purpose for cats under the name Covalzin .